Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period of rapid growth fueled by one of the most robust drug development pipelines in oncology. Notably, the biggest driver of market sales growth will be the anticipated approvals of immune checkpoint inhibitors from both multinational corporations as well as domestic developers, poised to transform the current treatment landscape. Biomarker-driven treatments are becoming increasingly attractive, highlighted by the development of Janssen’s Balversa for patients harboring FGFR mutations, and are expected to gain approval within the forecast period, resulting in more therapy options for metastatic patients. Nevertheless, chemotherapies reimbursed through China’s National Reimbursement Drug List will provide the core standard of care for most patients throughout the forecast period.
- How large are the drug-treatable bladder cancer populations and how will the drug-treatment rates change over time?
- What is the current state of the China bladder cancer market? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What are the key market access considerations of the most promising pipeline products? What sales/uptake could they secure in bladder cancer? What therapies of note are progressing in earlier phases?
- What are key drivers and constraints in the China bladder cancer market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other DRG research.
Diagnosed incidence of bladder cancer by disease stage and line of therapy. Clinically and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key bladder cancer regimens through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 11 drugs. Phase II: 7 drugs. Coverage of select early-phase products.
- China In-Depth
- China In-Depth: Bladder Cancer
Author(s): Steven F. Trueman, PhD; Oliver Blandy
Steve is a member of Decision Resources Group’s Infectious, Niche, and Rare Diseases (INRD) team. Currently, he provides analyses and content production on infections caused by the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Steve conducted his postdoctoral research on models of neurodegenerative disease in the Department of Biochemistry at Brandeis University. He earned a doctorate in biochemistry from the University of Massachusetts Medical School, Graduate School of Biomedical Sciences, where he studied protein translocation into the endoplasmic reticulum.
Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.